Pheophorbide A

CAT:
804-HY-125665-01
Size:
5 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Pheophorbide A - image 1

Pheophorbide A

  • Description:

    Pheophorbide A is an intermediate product in the chlorophyll degradation pathway. Pheophorbide A can be used as a photosensitizer. Pheophorbide A is a lymphatic vascular activator. Pheophorbide A has antitumor activity. Pheophorbide A can be used for human lymphatic vascular insufficiencies research[1][2][3].
  • UNSPSC:

    12352005
  • Hazard Statement:

    H302, H315, H319, H335
  • Target:

    Apoptosis
  • Type:

    Natural Products
  • Related Pathways:

    Apoptosis
  • Applications:

    Cancer-programmed cell death
  • Field of Research:

    Cancer; Cardiovascular Disease
  • Assay Protocol:

    https://www.medchemexpress.com/pheophorbide-a.html
  • Purity:

    95.0
  • Solubility:

    DMSO : 2 mg/mL (ultrasonic; warming; heat to 60°C) |Methanol : < 1 mg/mL (ultrasonic; warming; heat to 60°C)
  • Smiles:

    O=C ([C@@H]1/C (C (NC (/C=C2C (CC) =C3C) =C4C) =C4C1=O) =C (N=C (/C=C (C (C) =C/5C=C) \NC5=C/C3=N/2) [C@H]6C) \[C@H]6CCC (O) =O) OC
  • Molecular Formula:

    C35H36N4O5
  • Molecular Weight:

    592.68
  • Precautions:

    H302, H315, H319, H335
  • References & Citations:

    [1]Jihye Kim, et al. Pheophorbide a identified in an Eupatorium perfoliatum extract is a novel lymphatic vascular activator. Biomed Pharmacother. 2022 Mar;147:112664.|[2]Tang PM, et al. Pheophorbide a, an active compound isolated from Scutellaria barbata, possesses photodynamic activities by inducing apoptosis in human hepatocellular carcinoma. Cancer Biol Ther. 2006 Sep;5 (9) :1111-6.|[3]Ahn MY, et al. Pheophorbide a-mediated photodynamic therapy induces apoptotic cell death in murine oral squamous cell carcinoma in vitro and in vivo. Oncol Rep. 2012 Jun;27 (6) :1772-8.
  • Shipping Conditions:

    Blue Ice
  • Storage Conditions:

    -20°C, 3 years (Powder)
  • Scientific Category:

    Natural Products
  • Clinical Information:

    No Development Reported
  • CAS Number:

    15664-29-6